- InterView
- I know CRA grievances better than anyone else
- by Lee, Tak-Sun Nov 14, 2019 09:59am
- For CRA(Clinical Research Associate), it is very hard to communicate with many professional people. It's even harder if you don't have expertise. I wish my juniors would work with proud. I would like to have the pride of being an expert that communicates effectively with clinical expertise, monitors clinical practice, and leads clinical pra
- InterView
- "Use of RWD and AI in new drug development will increase”
- by Park, sangjun Nov 8, 2019 08:55am
- Global pharmaceutical companies have been increasingly attempting to implement artificial intelligence (AI) and real world data (RWD) to the process of developing new drugs believing that using AI can drastically reduce the development period and maximize treatment efficacy. Global leaders in the pharmaceutical industry such as Pfizer, GlaxoS
- InterView
- 50-year-old Pfizer Korea “For both patients and innovation"
- by Eo, Yun-Ho Nov 6, 2019 08:59am
- Half a century in Korean pharmaceutical industry, Pfizer Korea seems to have mastered ‘how to win’ in the Korean market. Pfizer took its first step into the Korean market as a joint corporation with Joongang Pharmaceutical in 1962 and founded Pfizer Korea in 1969. Except for a couple of times, Pfizer Korea’s sales have been the top amo
- InterView
- MFDS nizatidine investigation on NDMA still ongoing
- by Byun Kyung A Nov 1, 2019 04:45pm
- For the first time, Ministry of Food and Drug Safety (MFDS) officially announced its investigation on possibility of finding NDMA carcinogen in nizatidine, a structurally similar substance to ranitidine. Director Kim Nam-Soo of Pharmaceutical Management Division at MFDS convened a press conference on Oct. 29 and shared the news. The Pha
